Lead Product(s) : CX11
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CORXEL gets FDA Go-Ahead for Phase 2 Trial of CX11 in Obesity
Details : CX11, an investigational oral once-daily small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). It is being investigated for obesity and overweight.
Product Name : CX11
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 15, 2025
Lead Product(s) : CX11
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
